|
Getting your Trinity Audio player ready...
|
As 2025 draws to a close, it feels the right moment to reflect on an extraordinary year for Neuroendocrine Cancer UK – a year shaped by courage, collaboration and a community determined to make things better for everyone affected by neuroendocrine cancer.
For me, this reflection feels particularly personal. Although I am only a few months into the role of CEO, I have been part of Neuroendocrine Cancer UK for some time, and stepping into this role has given me an even deeper appreciation of the strength, generosity and resilience of our community. It is a privilege to work alongside all of you.
This has been a year of progress and hope. While neuroendocrine cancer remains complex and challenging to diagnose, together we have taken important steps forward through research, awareness and stronger support. What stands out most is that it is always the voices of those living with the disease that guide our work.
Highlights from 2025
Expanding Support and Connection
For me, this reflection feels particularly personal. Although I am only a few months into the role of CEO, I have been part of Neuroendocrine Cancer UK for some time, and stepping into this role has given me an even deeper appreciation of the strength, generosity and resilience of our community. It is a privilege to work alongside all of you.
This has been a year of progress and hope. While neuroendocrine cancer remains complex and challenging to diagnose, together we have taken important steps forward through research, awareness and stronger support. What stands out most is that it is always the voices of those living with the disease that guide our work.
Celebrating our Community – Hero Awards
Our Hero Awards gave us a powerful opportunity to celebrate the courage, compassion and dedication within our community. Hearing your stories continues to inspire us, and a huge congratulations to everyone nominated.
Raising Awareness Among GPs
We strengthened GP education by contributing to the Primary Care Society of Gastroenterology Ingest podcast and presenting at the GP conference in Birmingham, helping to highlight the crucial role of primary care in the early detection of neuroendocrine cancer.
Putting Patient Voices at the Heart of Research
Through the launch of the James Lind Alliance Priority Setting Partnership, we are enabling patients, carers and clinicians to identify the research questions that matter most.
Driving Research that Matters
We increased our investment in research, launching new grant funding in December to support better outcomes for patients.
Strengthening Data and Policy Work
Our work with national cancer registries marked significant progress in improving access to high-quality data to support better planning, services and outcomes. And we continue to push forward on improving access to earlier diagnosis and fairer access to effective treatments.
Thank you
None of this would be possible without the extraordinary strength of our community: patients, families, carers, clinicians, fundraisers, volunteers and supporters. Your generosity, resilience and determination continue to drive everything we do.
As we move into 2026, we remain deeply committed to supporting everyone affected by neuroendocrine cancer and working towards a future of earlier diagnosis, expert care and better outcomes.
Communities grow stronger because of the people in them – your part in ours matters most.
Thank you.
